IBDEI0LE ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10141,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10141,1,3,0)
 ;;=3^Blindness-One Eye
 ;;^UTILITY(U,$J,358.3,10141,1,4,0)
 ;;=4^369.62
 ;;^UTILITY(U,$J,358.3,10141,2)
 ;;=^268890
 ;;^UTILITY(U,$J,358.3,10142,0)
 ;;=377.00^^44^561^99
 ;;^UTILITY(U,$J,358.3,10142,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10142,1,3,0)
 ;;=3^Papilledema,Unspec
 ;;^UTILITY(U,$J,358.3,10142,1,4,0)
 ;;=4^377.00
 ;;^UTILITY(U,$J,358.3,10142,2)
 ;;=^89575
 ;;^UTILITY(U,$J,358.3,10143,0)
 ;;=377.02^^44^561^98
 ;;^UTILITY(U,$J,358.3,10143,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10143,1,3,0)
 ;;=3^Papilledema,Decreased Ocul Pressure
 ;;^UTILITY(U,$J,358.3,10143,1,4,0)
 ;;=4^377.02
 ;;^UTILITY(U,$J,358.3,10143,2)
 ;;=^269213
 ;;^UTILITY(U,$J,358.3,10144,0)
 ;;=377.03^^44^561^97
 ;;^UTILITY(U,$J,358.3,10144,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10144,1,3,0)
 ;;=3^Papilledema w/ Retina D/O
 ;;^UTILITY(U,$J,358.3,10144,1,4,0)
 ;;=4^377.03
 ;;^UTILITY(U,$J,358.3,10144,2)
 ;;=^269214
 ;;^UTILITY(U,$J,358.3,10145,0)
 ;;=377.04^^44^561^40
 ;;^UTILITY(U,$J,358.3,10145,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10145,1,3,0)
 ;;=3^Foster-Kennedy Syndrome
 ;;^UTILITY(U,$J,358.3,10145,1,4,0)
 ;;=4^377.04
 ;;^UTILITY(U,$J,358.3,10145,2)
 ;;=^265146
 ;;^UTILITY(U,$J,358.3,10146,0)
 ;;=377.11^^44^561^83
 ;;^UTILITY(U,$J,358.3,10146,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10146,1,3,0)
 ;;=3^Optic Atrophy,Primary
 ;;^UTILITY(U,$J,358.3,10146,1,4,0)
 ;;=4^377.11
 ;;^UTILITY(U,$J,358.3,10146,2)
 ;;=^269215
 ;;^UTILITY(U,$J,358.3,10147,0)
 ;;=377.12^^44^561^82
 ;;^UTILITY(U,$J,358.3,10147,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10147,1,3,0)
 ;;=3^Optic Atrophy,Postinflammatory
 ;;^UTILITY(U,$J,358.3,10147,1,4,0)
 ;;=4^377.12
 ;;^UTILITY(U,$J,358.3,10147,2)
 ;;=^269216
 ;;^UTILITY(U,$J,358.3,10148,0)
 ;;=377.15^^44^561^81
 ;;^UTILITY(U,$J,358.3,10148,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10148,1,3,0)
 ;;=3^Optic Atrophy,Partial
 ;;^UTILITY(U,$J,358.3,10148,1,4,0)
 ;;=4^377.15
 ;;^UTILITY(U,$J,358.3,10148,2)
 ;;=^269219
 ;;^UTILITY(U,$J,358.3,10149,0)
 ;;=377.16^^44^561^80
 ;;^UTILITY(U,$J,358.3,10149,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10149,1,3,0)
 ;;=3^Optic Atrophy,Leber's
 ;;^UTILITY(U,$J,358.3,10149,1,4,0)
 ;;=4^377.16
 ;;^UTILITY(U,$J,358.3,10149,2)
 ;;=^85931
 ;;^UTILITY(U,$J,358.3,10150,0)
 ;;=377.31^^44^561^94
 ;;^UTILITY(U,$J,358.3,10150,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10150,1,3,0)
 ;;=3^Optic Papillitis
 ;;^UTILITY(U,$J,358.3,10150,1,4,0)
 ;;=4^377.31
 ;;^UTILITY(U,$J,358.3,10150,2)
 ;;=^276874
 ;;^UTILITY(U,$J,358.3,10151,0)
 ;;=377.32^^44^561^89
 ;;^UTILITY(U,$J,358.3,10151,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10151,1,3,0)
 ;;=3^Optic Neuritis,Retrobulbar,Acute
 ;;^UTILITY(U,$J,358.3,10151,1,4,0)
 ;;=4^377.32
 ;;^UTILITY(U,$J,358.3,10151,2)
 ;;=^269225
 ;;^UTILITY(U,$J,358.3,10152,0)
 ;;=377.33^^44^561^92
 ;;^UTILITY(U,$J,358.3,10152,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10152,1,3,0)
 ;;=3^Optic Neuropathy,Nutritional
 ;;^UTILITY(U,$J,358.3,10152,1,4,0)
 ;;=4^377.33
 ;;^UTILITY(U,$J,358.3,10152,2)
 ;;=^269226
 ;;^UTILITY(U,$J,358.3,10153,0)
 ;;=377.39^^44^561^93
 ;;^UTILITY(U,$J,358.3,10153,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10153,1,3,0)
 ;;=3^Optic Neuropathy,Other
 ;;^UTILITY(U,$J,358.3,10153,1,4,0)
 ;;=4^377.39
 ;;^UTILITY(U,$J,358.3,10153,2)
 ;;=^87748
 ;;^UTILITY(U,$J,358.3,10154,0)
 ;;=377.42^^44^561^87
 ;;^UTILITY(U,$J,358.3,10154,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10154,1,3,0)
 ;;=3^Optic Nerve Sheaths Hemorrhage
 ;;
 ;;$END ROU IBDEI0LE
